Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 15/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15848653 | 1.00 | HCRTR2 (0.60) | HCRTR2GRM5PPARA | |
| SCHEMBL4954639 | 0.89 | HCRTR1 (0.56) | HCRTR2GRM5 | |
| SCHEMBL4954645 | 0.89 | HCRTR1 (0.56) | HCRTR2GRM5 | |
| SCHEMBL14153767 | 0.86 | GRM5 (0.54) | HCRTR2GRM5 | |
| SCHEMBL1990400 | 0.86 | CPT1A (0.59) | GRM5 | |
| SCHEMBL1990398 | 0.86 | CPT1A (0.59) | GRM5 | |
| SCHEMBL2275501 | 0.85 | SCD (0.50) | HCRTR2GRM5 | |
| SCHEMBL2275503 | 0.85 | SCD (0.50) | HCRTR2GRM5 | |
| SCHEMBL192547 | 0.85 | PPARA (0.58) | GRM5PPARA | |
| SCHEMBL192546 | 0.85 | PPARA (0.58) | GRM5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| WO-2014105926-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014105926-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | HCRTR2 4230/4885GRM5 1900/4885PPARA 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.